Dr. Mark A. Varney, PhD, Chief Executive Officer of Neurolixis, will present the latest preclinical data on NLX-112 at the 19th International Congress of Parkinson’s Disease and Movement Disorders to be held on June 14-18, 2015 in San Diego, California. The poster (#342) is entitled “NLX-112, a novel candidate for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.” NLX-112 (also known as befiradol) exhibits a promising profile in rat models of Parkinson’s disease, completely abolishing dyskinesias and also exhibiting potent antidepressant-like activity. Investigation of NLX-112 has been conducted with support from the Michael. J. Fox Foundation (see previous announcement) and results have recently been published (Iderberg et al., Experimental Neurology, 2015).

Neurolixis is pursuing opportunities to partner the clinical development of NLX-112contact us for further information.
For full details of the Parkinson and Movement Disorders Society congress see the meeting website.
Read the full press release:  pdf_symbol


Please enable the javascript to submit this form

Follow Neurolixis on: